It appears that inhibition of EPAC1 may be beneficial for targeting arrhythmia and heart failure [77,78], cancer [20], chronic pain [15], rickettsial infection [79], and obesity [17]. This evidence concerns the gene RAPGEF3 and obesity disorder.